Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 1997

View Archived Issues

MGI Pharma: Q3 1997 highlights

Bone Care: Q3 1997 highlights

Lilly: Q3 1997 highlights

BioCryst: Q3 1997 highlights

Atlantic's 2-5A improves efficacy of antisense compounds

First report of efficacy for rotavirus vaccine in a developing country

ADCON-L up for advisory committee review

Dusa reports positive phase III results for Levulan PDT

Hyal invests in breast cancer detection technology

Major advance in thalassemia research reported

Alza acquires rights to Ditropan

TBC-1269 enters phase II for treatment and prevention of asthma

Nicotrol launched in Austria as OTC

VEGF inhibitors described by Zeneca

Janssen discloses agents that promote gastrointestinal motility

New antidiabetic agents from Boehringer Mannheim

Abbott develops inhibitors of LT biosynthesis

Improved DNA topoisomerase poisons discovered at Rutgers

Anti-H. pylori cephems claimed by Fujisawa

New antimitotic agents presented by Kyowa Hakko

New DC-107 derivative presented at cancer meeting

Cellular target of new antitumor agent from Nippon Shinyaku identified

Nikken presents new modulator of multidrug resistance

NCA-0465: new antitumor indoloquinoxaline derivative

Preclinical studies on TZT-1027, an antitumor dolastatin 10 derivative

Taiho reports preclinical studies on TAS-103

Potent, topically active glucocorticoid from RPR shows potential for bronchial asthma

Development of antipsychotic agent discontinued

Synthetic retinoid with antiangiogenic/apoptosis-inducing effects from Taiho

MS-209 reverses MDR mediated by MRP and P-glycoprotein

Jenner Technologies changes name

Photofrin now available in France and Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.